Hemenway Trust Co LLC Sells 4,108 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Hemenway Trust Co LLC trimmed its stake in Vertex by 7.5% in Q4, selling 4,108 shares and leaving 51,017 shares worth about $23.13 million (1.8% of its portfolio).
• Vertex beat Q1 EPS ($4.47 vs. $4.24) with revenue up 8.3% driven by sales of new cystic fibrosis therapies, and reiterated full‑year 2026 revenue guidance of roughly $13.0–$13.1 billion.
• There was notable insider selling and a mixed market reaction—shares dipped and analysts trimmed near‑term price targets, though most maintain Buy/Outperform ratings (average target ≈ $554.83).

Hemenway Trust Co LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 7.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 51,017 shares of the pharmaceutical company's stock after selling 4,108 shares during the period. Vertex Pharmaceuticals comprises 1.8% of Hemenway Trust Co LLC's investment portfolio, making the stock its 22nd biggest position. Hemenway Trust Co LLC's holdings in Vertex Pharmaceuticals were worth $23,129,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Colonial Trust Co SC grew its position in Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 38 shares in the last quarter. Eagle Bay Advisors LLC bought a new stake in Vertex Pharmaceuticals in the 4th quarter worth about $29,000. Ares Financial Consulting LLC bought a new stake in Vertex Pharmaceuticals in the 4th quarter worth about $33,000. Financial Network Wealth Advisors LLC grew its position in Vertex Pharmaceuticals by 50.9% in the 3rd quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company's stock worth $34,000 after purchasing an additional 29 shares in the last quarter. Finally, Archer Investment Corp grew its position in Vertex Pharmaceuticals by 89.7% in the 4th quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company's stock worth $34,000 after purchasing an additional 35 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat on EPS and showed revenue growth driven by product sales; management highlighted broad portfolio strength and pipeline progress, supporting longer‑term growth thesis. Business Wire: Vertex Reports First Quarter 2026 Financial Results
• Positive Sentiment: Sales of new CF therapies and other recently launched products accelerated, contributing materially to product revenue growth and suggesting multiple near‑term commercial growth engines. Reuters: Vertex tops profit estimates as sales of new cystic fibrosis drug surge
• Neutral Sentiment: Vertex reiterated full‑year 2026 revenue guidance (~$13.0B–$13.1B), roughly in line with consensus — supportive for guidance stability but not a clear upside catalyst. Investor Slide Deck / Press Release (Q1 2026)
• Neutral Sentiment: Analysts revised models and price targets after the Q1 release — many maintained Outperform/Buy views but trimmed targets, reflecting mixed near‑term readings despite constructive longer‑term views. Benzinga: These Analysts Revise Their Forecasts On Vertex After Q1 Earnings
• Negative Sentiment: Insider selling was reported this week (EVP Joy Liu sold 1,104 shares; director Sangeeta Bhatia sold 318 shares). Trades were executed under 10b5‑1 plans, but active insider sales can weigh on sentiment. SEC Form 4 (Joy Liu) SEC Form 4 (Sangeeta Bhatia)
• Negative Sentiment: Shares dipped after the mixed report (EPS/revenue beats but some metrics and commentary left investors cautious), prompting near‑term profit‑taking and PT trims. Yahoo Finance: Vertex Dips On Mixed First‑Quarter Report

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $424.36 on Wednesday. Vertex Pharmaceuticals Incorporated has a 1 year low of $362.50 and a 1 year high of $507.92. The stock has a market capitalization of $107.94 billion, a PE ratio of 25.17, a P/E/G ratio of 1.87 and a beta of 0.30. The company's 50 day simple moving average is $452.77 and its two-hundred day simple moving average is $449.59.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 24.41%. The business had revenue of $2.99 billion for the quarter, compared to analysts' expectations of $2.99 billion. During the same period in the prior year, the company posted $4.06 EPS. The business's revenue for the quarter was up 8.3% compared to the same quarter last year. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.81 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on VRTX shares. Scotiabank increased their target price on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an "outperform" rating in a research report on Friday, February 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $590.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Morgan Stanley increased their target price on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an "overweight" rating in a research report on Tuesday. Weiss Ratings downgraded shares of Vertex Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, April 14th. Finally, Bank of America increased their target price on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the company a "buy" rating in a research report on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $554.83.

Insider Activity

In other news, EVP Mark E. Bunnage sold 620 shares of the firm's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $301,537.00. Following the sale, the executive vice president owned 7,284 shares in the company, valued at approximately $3,542,573.40. This trade represents a 7.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Carmen Bozic sold 2,329 shares of the firm's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $481.79, for a total transaction of $1,122,088.91. Following the sale, the chief marketing officer owned 35,405 shares in the company, valued at approximately $17,057,774.95. This trade represents a 6.17% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 81,853 shares of company stock worth $38,479,135. Corporate insiders own 0.20% of the company's stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.